Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 22, issue 6, 2024

Economic Epidemiology: A Framework to Study Interactions of Epidemics and the Economy pp. 767-769

Aditya Goenka and Lin Liu

Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland pp. 771-781

Claire Gorry, Maria Daly, Rosealeen Barrett, Karen Finnigan, Amelia Smith, Stephen Doran, Bernard Duggan, Sarah Clarke and Michael Barry

The Development of a New Approach for the Harmonized Multi-Sectoral and Multi-Country Cost Valuation of Services: The PECUNIA Reference Unit Cost (RUC) Templates pp. 783-796

Susanne Mayer, Michael Berger, Nataša Perić, Claudia Fischer, Alexander Konnopka, Valentin Brodszky, Silvia M. A. A. Evers, Leona Hakkaart- van Roijen, Mencia Ruiz Guitérrez Colosia, Luis Salvador-Carulla, A-La Park, Joanna Thorn, Lidia García-Pérez and Judit Simon

Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges pp. 797-804

Oscar Espinosa Acuña, Paul Rodríguez-Lesmes, Giancarlo Romano, Esteban Orozco, Sergio Basto, Diego Ávila, Lorena Mesa and Hernán Enríquez

Sedaconda ACD-S for Sedation with Volatile Anaesthetics in Intensive Care: A NICE Medical Technologies Guidance pp. 805-813

Michal Pruski, Susan O’Connell, Laura Knight and Rhys Morris

Impact of Government-Funded Health Insurance on Out-of-Pocket Expenditure and Quality of Hospital-Based Care in Indian States of Madhya Pradesh and Maharashtra pp. 815-825

Samir Garg, Kirtti Kumar Bebarta, Narayan Tripathi and Vikash Ranjan Keshri

Are Drug Novelty Characteristics Associated With Greater Health Benefits? pp. 827-832

A. Alex Levine, Daniel E. Enright, Katherine A. Clifford, Stacey Kowal and James D. Chambers

Financial Literacy and Mental Health: Empirical Evidence from China pp. 833-847

Naijie Guan, Alessandra Guariglia, Patrick Moore and Hareth Al-Janabi

Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling pp. 849-860

Kailu Wang, Ho-Man Shum, Carrie Ho-Kwan Yam, Yushan Wu, Eliza Lai-Yi Wong and Eng-Kiong Yeoh

The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes pp. 861-869

Ting Zhao, Michelle Tew, Talitha Feenstra, Pieter Baal, Michael Willis, William J. Valentine, Philip M. Clarke, Barnaby Hunt, James Altunkaya, An Tran-Duy, Richard F. Pollock, Samuel J. P. Malkin, Andreas Nilsson, Phil McEwan, Volker Foos, Jose Leal, Elbert S. Huang, Neda Laiteerapong, Mark Lamotte, Harry Smolen, Jianchao Quan, Luís Martins, Mafalda Ramos and Andrew J. Palmer

A Contingent Valuation Study for Use in Valuing Public Goods with Health Externalities: The Case of Street Pianos pp. 871-883

Aikaterini Papadopoulou, Helen Mason and Cam Donaldson

Cost-Utility Analysis of TNF-α Inhibitors, B Cell Inhibitors, and JAK Inhibitors Versus csDMARDs for Rheumatoid Arthritis Treatment pp. 885-896

Madhumitha Haridoss, Akhil Sasidharan, Sajith Kumar, Kavitha Rajsekar, Krishnamurthy Venkataraman and Bhavani Shankara Bagepally

Volume 22, issue 5, 2024

Cost of Carbon in the Total Cost of Healthcare Procedures: A Methodological Challenge pp. 599-607

Paul-Simon Pugliesi, Laurie Marrauld and Catherine Lejeune

A Multi-dimensional Framework of Valued Output for Primary Care in England pp. 609-617

Margherita Neri, Patricia Cubi-Molla and Graham Cookson

Informing Structural Assumptions for Three State Oncology Cost-Effectiveness Models through Model Efficiency and Fit pp. 619-628

Dominic Muston

Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally pp. 629-652

Sabine Vogler, Katharina Habimana, Manuel Alexander Haasis and Stefan Fischer

Are Medical Device Characteristics Included in HTA Methods Guidelines and Reports? A Brief Review pp. 653-664

Rituparna Basu, Simon Eggington, Natalie Hallas and Liesl Strachan

The Economic Impact of Community Paramedics Within Emergency Medical Services: A Systematic Review pp. 665-684

Matt Wilkinson-Stokes, Michelle Tew, Celene Y. L. Yap, Di Crellin and Marie Gerdtz

The Cost-Effectiveness of Primary Prevention Interventions for Skin Cancer: An Updated Systematic Review pp. 685-700

Louisa G. Collins, Ryan Gage, Craig Sinclair and Daniel Lindsay

Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa pp. 701-715

Pim W. M. Dorst, Simon Pol, Piero Olliaro, Sabine Dittrich, Juvenal Nkeramahame, Maarten J. Postma, Cornelis Boersma and Antoinette D. I. Asselt

How Does the New Australian EQ-5D-5L Value Set Impact Utility Scores? Analysis of Data from the Australian Orthopaedic Association National Joint Replacement Registry pp. 717-724

Ilana N. Ackerman, Richard Norman, Ian A. Harris, Kara Cashman, Michelle Lorimer, Stephen Gill, Peter Lewis and Sze-Ee Soh

Employing Real-World Evidence for the Economic Evaluation of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation in Thailand pp. 725-734

Rungroj Krittayaphong and Unchalee Permsuwan

Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective pp. 735-747

Maryia Zhdanava, Jacqueline Pesa, Porpong Boonmak, Samuel Schwartzbein, Qian Cai, Dominic Pilon, Zia Choudhry, Marie-Hélène Lafeuille, Patrick Lefebvre and Nizar Souayah

Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study pp. 749-765

Theodore Laetsch, Jie Zhang, Hongbo Yang, Yanwen Xie, Dudan Zhang and Louis Garrison

Volume 22, issue 4, 2024

Health Economics in a World of Uneconomic Growth pp. 427-433

Martin Hensher, Gerry McCartney and Eleanor Ochodo

Is Economic Evaluation and Care Commissioning Focused on Achieving the Same Outcomes? Resource-Allocation Considerations and Challenges Using England as a Case Study pp. 435-445

Matthew Franklin, Sebastian Hinde, Rachael Maree Hunter, Gerry Richardson and William Whittaker

#SharingHEOR: Developing Modern Media for Communication and Dissemination of Health Economics and Outcomes Research pp. 447-455

Davene R. Wright, Mikaela Batista and Tim Wrightson

Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis pp. 457-470

Enxue Chang, Haofei Li, Wanji Zheng, Lan Zhou, Yanni Jia, Wen Gu, Yiyin Cao, Xiaoying Zhu, Juan Xu, Bo Liu, Mao You, Kejun Liu, Mingsi Wang and Weidong Huang

Measurement of Catastrophic Health Expenditure in India: A Systematic Review and Meta-Analysis pp. 471-483

Umenthala Srikanth Reddy

Cost of Low-Value Imaging Worldwide: A Systematic Review pp. 485-501

Elin Kjelle, Ingrid Øfsti Brandsæter, Eivind Richter Andersen and Bjørn Morten Hofmann

Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment pp. 503-525

Mohsen Ghaffari Darab, Lidia Engel, Dennis Henzler, Michael Lauerer, Eckhard Nagel, Vicki Brown and Cathrine Mihalopoulos

A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening pp. 527-542

Stuart J. Wright, Ewan Gray, Gabriel Rogers, Anna Donten and Katherine Payne

Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden pp. 543-554

Chiara Malmberg, Magnus Värendh, Patric Berling, Mata Charokopou and Erik Eklund

Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China pp. 555-568

Ningxin Ding, Huixuan Zhou, Chen Chen, Hui Chen and Yunfeng Shi

Cost-Effectiveness of Novel Agent Regimens for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients in India pp. 569-582

Jyoti Dixit, Pankaj Malhotra, Nikita Mehra, Anisha Mathew, Lalit Kumar, Ashish Singh, Nidhi Gupta, Manjunath Nookala Krishnamurthy, Partha Sarathi Roy, Amal Chandra Kataki, Sudeep Gupta and Shankar Prinja

The Hidden Toll of Psychological Distress in Australian Adults and Its Impact on Health-Related Quality of Life Measured as Health State Utilities pp. 583-598

Muhammad Iftikhar ul Husnain, Mohammad Hajizadeh, Hasnat Ahmad and Rasheda Khanam

Volume 22, issue 3, 2024

Local Level Economic Evaluation: What is it? What is its Value? Is it Sustainable? pp. 273-281

Jonathan Karnon, Andrew Partington, Jodi Gray, Aubyn Pincombe and Timothy Schultz

What Interventions are Cost Effective in Reducing Violence Against Women? A Scoping Review pp. 283-296

Lauren Sheppard, Moosa Alsubhi, Vicki Brown, Ha Le, Kim Robinson and Marj Moodie

A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries pp. 297-313

Néboa Zozaya, Javier Villaseca, Irene Fernández, Fernando Abdalla, Benito Cadenas-Noreña, Miguel Ángel Calleja, Pedro Gómez-Pajuelo, Jorge Mestre-Ferrándiz, Juan Oliva-Moreno, José Luis Trillo and Álvaro Hidalgo-Vega

Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose? pp. 315-329

Helen Dakin and Apostolos Tsiachristas

Simplified Methods for Modelling Dependent Parameters in Health Economic Evaluations: A Tutorial pp. 331-341

Xuanqian Xie, Alexis K. Schaink, Sichen Liu, Myra Wang, Juan David Rios and Andrei Volodin

Comparing Preferences for Disease Profiles: A Discrete Choice Experiment from a US Societal Perspective pp. 343-352

Karissa M. Johnston, Ivana F. Audhya, Jessica Dunne, David Feeny, Peter Neumann, Daniel C. Malone, Shelagh M. Szabo and Katherine L. Gooch

Health Interventions May Have Divergent Impacts on Health and Economic Equity: A Case Study of the Community-Based Hypertension Improvement Project in Ghana pp. 353-362

Yizhi Liang, Yuqian Lin and Boshen Jiao

The Impact of Raising Alcohol Taxes on Government Tax Revenue: Insights from Five European Countries pp. 363-374

Jakob Manthey, Inese Gobiņa, Laura Isajeva, Jarosław Neneman, Rainer Reile, Mindaugas Štelemėkas and Jürgen Rehm

Estimating Transition Probabilities for Modeling Major Depression in Adolescents by Sex and Race or Ethnicity Combinations in the USA pp. 375-390

Tran T. Doan, David W. Hutton, Davene R. Wright and Lisa A. Prosser

Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with Duration pp. 391-400

Takeru Shiroiwa and Takashi Fukuda

Treatment Preferences of Adolescents and Young Adults with Depressive Symptoms: A Discrete Choice Experiment pp. 401-413

Ruth C. Waumans, Anna D. T. Muntingh, Jorien Veldwijk, Adriaan Hoogendoorn, Anton J. L. M. Balkom and Neeltje M. Batelaan

Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India pp. 415-426

Nidhi Gupta, Dharna Gupta, Kiran Gopal Vaska and Shankar Prinja

Volume 22, issue 2, 2024

Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses pp. 129-130

Jonathan Karnon and Clarabelle Pham

Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice Recommendations pp. 131-144

Bethany Shinkins, A. Joy Allen, James Karichu, Louis P. Garrison and Brigitta U. Monz

Participatory Value Evaluation (PVE): A New Preference-Elicitation Method for Decision Making in Healthcare pp. 145-154

Sander Boxebeld, Niek Mouter and Job Exel

An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone pp. 155-164

Aidan Hollis

The Limitations and Potentials of Evaluating Economic Aspects of Community-Based Health Promotion: A Critical Review pp. 165-179

Philipp Weber, Leonie Birkholz, Riccarda Straub, Simone Kohler, Natalie Helsper, Lea Dippon, Klaus Pfeifer, Alfred Rütten and Jana Semrau

Cost Effectiveness of Deep Brain Stimulation for Parkinson’s Disease: A Systematic Review pp. 181-192

Akhil Sasidharan, Bhavani Shankara Bagepally and S Sajith Kumar

Should Commercial Diagnostic Testing Be Stimulated or Discouraged? Analyzing Willingness-to-Pay and Market Externalities of Three Commercial Diagnostic Tests in The Netherlands pp. 193-207

Niek Stadhouders, Ella Vliet, Anne E.M. Brabers, Wieteke Dijk and Suzanne Onstwedder

Do Informal Care Recipients Internalise Carer Burden? Examining the Impact of Informal Care Receipt on Health Behaviours pp. 209-225

Jack Elliott, Igor Francetic, Rachel Meacock and Matt Sutton

Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L pp. 227-242

Xin Zhang, Karin M. Vermeulen and Paul F. M. Krabbe

Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation pp. 243-254

Janet Bouttell, Heather Fraser, John R. Goodlad, David Hopkins, Pam McKay, Karin A. Oien, Bruce Seligmann, Stephan Delft and Neil Hawkins

Health Service Utilisation of People Living with Psychosis: Validity of Self-report Compared with Administrative Data in a Randomised Controlled Trial pp. 255-264

Vergil Dolar, Mary Lou Chatterton, Long Khanh-Dao Le, Cathrine Mihalopoulos, Neil Thomas and Lidia Engel

Comment on: “Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses” pp. 265-267

Natalia Kunst, Annisa Siu, Michael Drummond, Sabine Grimm, Janneke Grutters, Don Husereau, Hendrik Koffijberg, Claire Rothery, Edward C. F. Wilson and Anna Heath

Correction to: Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L pp. 269-269

Xin Zhang, Karin M. Vermeulen and Paul F. M. Krabbe

Correction: Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance pp. 271-272

Jake T. W. Williams, Katy J. L. Bell, Rachael L. Morton and Mbathio Dieng

Volume 22, issue 1, 2024

The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA pp. 5-7

Lindsay Allen

Modelling Informal Carers’ Health-Related Quality of Life: Challenges for Economic Evaluation pp. 9-16

Becky Pennington and Hareth Al-Janabi

A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana pp. 17-32

Aashima and Rajesh Sharma

Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review pp. 33-48

Yan Li, Pingyu Chen, Xintian Wang, Qian Peng, Shixia Xu, Aixia Ma and Hongchao Li

Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom pp. 49-60

Max Kindred, Zahratu Shabrina and Neily Zakiyah

Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older pp. 61-71

Shoroq M. Altawalbeh, Angela R. Wateska, Mary Patricia Nowalk, Chyongchiou J. Lin, Lee H. Harrison, William Schaffner, Richard K. Zimmerman and Kenneth J. Smith

Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy pp. 73-84

Constanza Vargas, Rebecca Addo, Milena Lewandowska, Philip Haywood, Richard Abreu Lourenco and Stephen Goodall

Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA pp. 85-95

Rui Li, Pengyi Lu, Christopher K. Fairley, José A. Pagán, Wenyi Hu, Qianqian Yang, Guihua Zhuang, Mingwang Shen, Yan Li and Lei Zhang

VOLY: The Monetary Value of a Life-Year at the End of Patients’ Lives pp. 97-106

Elizabeta Ribarić, Ismar Velić and Ana Bobinac

Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia pp. 107-122

Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman and Maarten J. IJzerman

Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022” pp. 123-124

Sieta T. Vries, Noral Huda S. Al-Mugoter, Irena Petkoska, Stefan Verweij, André J. A. Elferink and Peter G. M. Mol

Comment on: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?” pp. 125-126

Afschin Gandjour

Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?” pp. 127-128

Melanie Büssgen and Tom Stargardt